DK1117659T3 - Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser - Google Patents
Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaserInfo
- Publication number
- DK1117659T3 DK1117659T3 DK99948410T DK99948410T DK1117659T3 DK 1117659 T3 DK1117659 T3 DK 1117659T3 DK 99948410 T DK99948410 T DK 99948410T DK 99948410 T DK99948410 T DK 99948410T DK 1117659 T3 DK1117659 T3 DK 1117659T3
- Authority
- DK
- Denmark
- Prior art keywords
- cyanoquinolines
- inhibitors
- substituted
- tyrosine kinases
- protein tyrosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16280298A | 1998-09-29 | 1998-09-29 | |
PCT/US1999/022054 WO2000018761A1 (en) | 1998-09-29 | 1999-09-22 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1117659T3 true DK1117659T3 (da) | 2004-03-22 |
Family
ID=22587189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99948410T DK1117659T3 (da) | 1998-09-29 | 1999-09-22 | Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1117659B1 (da) |
JP (1) | JP4548642B2 (da) |
KR (1) | KR100705142B1 (da) |
CN (1) | CN1165532C (da) |
AR (1) | AR035155A1 (da) |
AT (1) | ATE255575T1 (da) |
AU (1) | AU763669B2 (da) |
BR (1) | BR9914167B1 (da) |
CA (1) | CA2344169C (da) |
CZ (1) | CZ303899B6 (da) |
DE (1) | DE69913364T2 (da) |
DK (1) | DK1117659T3 (da) |
EA (1) | EA004436B1 (da) |
ES (1) | ES2211175T3 (da) |
HK (1) | HK1035188A1 (da) |
HU (1) | HUP0103520A3 (da) |
IL (2) | IL142121A0 (da) |
NO (1) | NO324563B1 (da) |
NZ (1) | NZ510551A (da) |
PL (1) | PL201475B1 (da) |
PT (1) | PT1117659E (da) |
SK (1) | SK284846B6 (da) |
TW (1) | TWI233437B (da) |
UA (1) | UA72749C2 (da) |
WO (1) | WO2000018761A1 (da) |
ZA (1) | ZA200102729B (da) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
GB9910580D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2001079198A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
JP2004505964A (ja) * | 2000-08-09 | 2004-02-26 | アストラゼネカ アクチボラグ | Vegf阻害活性を有するキノリン誘導体 |
US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
WO2002036570A1 (en) * | 2000-11-02 | 2002-05-10 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
JP4307843B2 (ja) | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
EP1412367A4 (en) | 2001-06-21 | 2006-05-03 | Ariad Pharma Inc | NEW CHINOLINE AND ITS USE |
DE60215178T2 (de) | 2001-07-16 | 2007-08-23 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
CA2467573A1 (en) * | 2001-11-27 | 2003-06-19 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
WO2003047584A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
AU2002347360A1 (en) * | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours |
WO2003047583A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours |
WO2003047582A1 (en) * | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
GB0129099D0 (en) * | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
EP1477481B1 (en) * | 2002-01-28 | 2009-07-22 | Ube Industries, Ltd. | Process for producing quinazolin-4-one derivative |
DE60327323D1 (de) | 2002-07-09 | 2009-06-04 | Astrazeneca Ab | Chinazoline derivative und ihre anwendung in der krebsbehandlung |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
CN101423497A (zh) * | 2002-07-19 | 2009-05-06 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物 |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
PT1562955E (pt) | 2002-11-04 | 2008-05-05 | Astrazeneca Ab | Derivados de quinazolina como inibidores da scr tirosina-cinase |
US7153889B2 (en) | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
US20070036795A1 (en) | 2003-06-09 | 2007-02-15 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
SG151288A1 (en) | 2003-12-18 | 2009-04-30 | Janssen Pharmaceutica Nv | 3-cyano-quinoline derivatives with antiproliferative activity |
EP1697384B1 (en) | 2003-12-18 | 2008-04-02 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents |
CN1890234A (zh) * | 2003-12-23 | 2007-01-03 | 辉瑞大药厂 | 新颖的喹啉衍生物 |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
PL1735348T3 (pl) | 2004-03-19 | 2012-11-30 | Imclone Llc | Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
RU2007143161A (ru) * | 2005-05-25 | 2009-07-10 | Вайет (Us) | Способы синтеза замещенных 3-цианохинов и их продуктов |
CA2678008C (en) | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
DE602006013828D1 (en) | 2005-07-27 | 2010-06-02 | Hoffmann La Roche | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren |
EP1915368A1 (en) | 2005-08-08 | 2008-04-30 | Pfizer, Inc. | Salts and polymorphs of a vergf-r inhibitor |
ATE520979T1 (de) | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
PL2010496T3 (pl) * | 2006-04-14 | 2011-01-31 | Astrazeneca Ab | 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R |
KR20090018612A (ko) * | 2006-06-13 | 2009-02-20 | 와이어쓰 | 단백질 키나제 억제제로서의 치환된 3-시아노피리딘 |
EP2044084B1 (en) | 2006-07-13 | 2016-02-17 | Janssen Pharmaceutica NV | Mtki quinazoline derivatives |
AU2008265104B2 (en) * | 2007-06-21 | 2013-09-12 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
TWI459947B (zh) * | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
EP2185562B1 (en) | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
CN101148439B (zh) * | 2007-09-14 | 2011-06-22 | 东南大学 | 一种吉非替尼的制备方法 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102020639A (zh) | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
US20120220594A1 (en) | 2009-10-30 | 2012-08-30 | Bristol-Meyers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
GB0922302D0 (en) * | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
JP5730389B2 (ja) | 2010-06-09 | 2015-06-10 | 天津和美生物技術有限公司 | シアノキノリン誘導体 |
CN102958919A (zh) * | 2010-07-02 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 新的四氢喹啉衍生物 |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
US20140309229A1 (en) | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
BR112015020139A2 (pt) | 2013-02-20 | 2017-07-18 | Kala Pharmaceuticals Inc | compostos terapêuticos e usos dos mesmos |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
ES2860695T3 (es) | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN109688818A (zh) | 2016-09-08 | 2019-04-26 | 卡拉制药公司 | 治疗化合物的晶型及其用途 |
WO2018078143A1 (en) | 2016-10-28 | 2018-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy |
AU2018289864B2 (en) * | 2017-06-23 | 2022-03-31 | Cstone Pharmaceuticals | Coumarin-like cyclic compound as MEK inhibitor and use thereof |
CA3098428A1 (en) | 2018-04-18 | 2019-10-24 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
AU2020393384A1 (en) * | 2019-11-28 | 2022-06-09 | Bayer Aktiengesellschaft | Substituted aminoquinolones as DGKalpha inhibitors for immune activation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
-
1999
- 1999-09-22 AU AU61593/99A patent/AU763669B2/en not_active Expired
- 1999-09-22 AT AT99948410T patent/ATE255575T1/de active
- 1999-09-22 EA EA200100411A patent/EA004436B1/ru not_active IP Right Cessation
- 1999-09-22 IL IL14212199A patent/IL142121A0/xx active IP Right Grant
- 1999-09-22 PT PT99948410T patent/PT1117659E/pt unknown
- 1999-09-22 CA CA2344169A patent/CA2344169C/en not_active Expired - Lifetime
- 1999-09-22 DK DK99948410T patent/DK1117659T3/da active
- 1999-09-22 BR BRPI9914167-1A patent/BR9914167B1/pt not_active IP Right Cessation
- 1999-09-22 NZ NZ510551A patent/NZ510551A/xx not_active IP Right Cessation
- 1999-09-22 HU HU0103520A patent/HUP0103520A3/hu unknown
- 1999-09-22 SK SK413-2001A patent/SK284846B6/sk not_active IP Right Cessation
- 1999-09-22 JP JP2000572221A patent/JP4548642B2/ja not_active Expired - Lifetime
- 1999-09-22 CZ CZ20011038A patent/CZ303899B6/cs not_active IP Right Cessation
- 1999-09-22 PL PL346934A patent/PL201475B1/pl unknown
- 1999-09-22 DE DE69913364T patent/DE69913364T2/de not_active Expired - Lifetime
- 1999-09-22 ES ES99948410T patent/ES2211175T3/es not_active Expired - Lifetime
- 1999-09-22 KR KR1020017003892A patent/KR100705142B1/ko active IP Right Grant
- 1999-09-22 WO PCT/US1999/022054 patent/WO2000018761A1/en not_active Application Discontinuation
- 1999-09-22 EP EP99948410A patent/EP1117659B1/en not_active Expired - Lifetime
- 1999-09-22 UA UA2001042929A patent/UA72749C2/uk unknown
- 1999-09-22 CN CNB998113697A patent/CN1165532C/zh not_active Expired - Lifetime
- 1999-09-28 AR ARP990104884A patent/AR035155A1/es active IP Right Grant
- 1999-09-29 TW TW088116630A patent/TWI233437B/zh not_active IP Right Cessation
-
2001
- 2001-03-20 IL IL142121A patent/IL142121A/en not_active IP Right Cessation
- 2001-03-28 NO NO20011575A patent/NO324563B1/no not_active IP Right Cessation
- 2001-04-03 ZA ZA200102729A patent/ZA200102729B/en unknown
- 2001-08-17 HK HK01105823A patent/HK1035188A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1117659T3 (da) | Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser | |
NO20011574D0 (no) | Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer | |
CY2008015I1 (el) | Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης | |
DK0912559T3 (da) | Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer | |
NO20011356D0 (no) | Pyrrolopyrimidiner som proteinkinase-inhibitorer | |
DZ3223A1 (fr) | Inhibiteurs de tyrosine kinases | |
NO990123D0 (no) | Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer | |
NO20014970D0 (no) | Cyklisk protein-tyrosin-kinase-inhibitor | |
DK1200435T3 (da) | Purinderivathæmmere af tyrosinproteinkinase SYK | |
DK1330452T3 (da) | Pyrazinderivater som modulatorer af tyrosinkinaser | |
DK1532138T3 (da) | Inhibitorer af tyrosinkinaser | |
DK1183033T3 (da) | Pyrrolotriazininhibitorer af kinaser | |
IS6968A (is) | Nýir týrósínkínasa tálmar | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
NO20035728D0 (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
IS5772A (is) | Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum | |
DK1171440T3 (da) | Substituerede 3-cyano-[1,7]-, [1,5]- og [1,8]-naphthyridininhibitorer af tyrosinkinaser |